Is systems biology the key to preventing the next pandemic?

Future Virology

Volumn 4, Issue 6, 2009, Pages 553-561

  Tisoncik, Jennifer R ^a   Belisle, Sarah E ^a   Diamond, Deborah L ^a   Korth, Marcus J ^a   Katze, Michael G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiviral therapeutics; Genomics; Metabolomics; Next generation sequencing; Proteomics; Systems biology; Vaccines; Viral pandemics

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; FGI 106; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; OSELTAMIVIR; ROSCOVITINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; GENETIC VARIABILITY; GENOMICS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A H1N1; METABOLOMICS; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS HEMORRHAGIC FEVER; VIRUS MUTATION; VIRUS PATHOGENESIS;

AVES; HEPATITIS C VIRUS; ORTHOMYXOVIRIDAE; SARS CORONAVIRUS;

EID: 73949103782     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.53     Document Type: Review

References (47)

1. Johnson NP, Mueller J: Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76(1), 105-115 (2002).
2. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH: Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-1920 pandemic: a quantitative analysis. Lancet 368(9554), 2211-2218 (2006).
3. Tumpey TM, Basler CF, Aguilar PV et al.: Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310(5745), 77-80 (2005).
4. Kash JC, Tumpey TM, Proll SC et al.: Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443(7111), 578-581 (2006).
5. Kobasa D, Jones SM, Shinya K et al.: Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445(7125), 319-323 (2007).
6. Baas T, Baskin CR, Diamond DL et al.: Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J. Virol. 80(21), 10813-10828 (2006).
7. Wolff GL, Kodell RL, Moore SR, Cooney CA: Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 12(11), 949-957 (1998).
8. Chesler EJ, Miller DR, Branstetter LR et al.: The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm. Genome 19(6), 382-389 (2008). ■ Reports on the ongoing Collaborative Cross project initiated in 2005, which has bred a large population of genetically diverse mouse strains designed to support systems genetics analysis.
9. Churchill GA, Airey DC, Allayee H et al.: The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36(11), 1133-1137 (2004).
10. Dolan MJ, Kulkarni H, Camargo JF et al.: CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8(12), 1324-1336 (2007).
11. Fellay J, Shianna KV, Ge D et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 317(5840), 944-947 (2007).
12. Limou S, Le Clerc S, Coulonges C et al.: Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 199(3), 419-426 (2009).
13. Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). ■ Demonstrates that CCL3L1-CCR5 genetic variation influences reconstitution of CD4+ T cells in HIV patients receiving highly active antiretroviral therapy.
14. Kulkarni H, Agan BK, Marconi VC et al.: CCL3L1-CCR5 genotype improves the assessment of AIDS risk in HIV-1-infected individuals. PLoS One 3(9), e3165 (2008).
15. Catano G, Kulkarni H, He W et al.: HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLAB*57 alleles. PLoS One 3(11), e3636 (2008).
16. Shao W, Lazaryan A, Dorak MT et al.: Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression. AIDS 20(12), 1583-1590 (2006).
17. Le QM, Kiso M, Someya K et al.: Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
18. Dharan NJ, Gubareva LV, Meyer JJ et al.: Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301(10), 1034-1041 (2009).
19. McHutchison JG, Everson GT, Gordon SC et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360(18), 1827-1838 (2009).
20. Hezode C, Forestier N, Dusheiko G et al.: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839-1850 (2009).
21. Agbottah E, de La Fuente C, Nekhai S et al.: Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280(4), 3029-3042 (2005).
22. Salerno D, Hasham MG, Marshall R et al.: Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 405(1-2), 65-78 (2007).
23. + cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. J. Virol. 81(14), 7571-7583 (2007).
24. Chan EY, Sutton JN, Jacobs JM et al.: Dynamic host energetics and cytoskeletal proteomes in human immunodeficiency virus type 1-infected human primary CD4 cells: analysis by multiplexed label-free mass spectrometry. J. Virol. 83(18), 9283-9295 (2009). ■ Demonstrates the use of proteomics in an HIV-1 infection system to profile virus-induced cellular perturbations during the course of infection and the effects of protein abundance changes in the presence of reverse-transcriptase inhibitor.
25. Martinson JA, Tenorio AR, Montoya CJ et al.: Impact of class A, B and C CpGoligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology 120(4), 526-535 (2007).
26. Gulick RM, Lalezari J, Goodrich J et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359(14), 1429-1441 (2008).
27. Tan SL, Ganji G, Paeper B, Proll S, Katze MG: Systems biology and the host response to viral infection. Nat. Biotechnol. 25(12), 1383-1389 (2007).
28. Brass AL, Dykxhoorn DM, Benita Y et al.: Identification of host proteins required for HIV infection through a functional genomic screen. Science 319(5865), 921-926 (2008).
29. Hao L, Sakurai A, Watanabe T et al.: Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454(7206), 890-893 (2008).
30. Aman MJ, Kinch MS, Warfield K et al.: Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83(3), 245-251 (2009).
31. Diaz L, Cassellaa J, Bonaviaa A et al. Recruitment of the TSG101/ESCRT-I machinery in host cells by influenza virus: implications for broad-spectrum therapy. Presented at: 22nd International Conference on Antiviral Research. Miami, FL, USA, 3-7 May 2009.
32. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A et al.: Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J. Virol. 81(21), 11817-11827 (2007). ■ Showcases the use of transcriptional profiling integrated with proteomic analysis to investigate innate immune responses in a nonhuman primate model of influenza infection with the potential to identify immune correlates of vaccination.
33. Buchbinder SP, Mehrotra DV, Duerr A et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
34. Lederer S, Favre D, Walters KA et al.: Transcriptional profiling in pathogenic and nonpathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog. 5(2), e1000296 (2009).
35. Favre D, Lederer S, Kanwar B et al.: Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5(2), e1000295 (2009). ■ Functional genomics suggests a mechanism differentiating pathogenic from nonpathogenic SIV infection in nonhuman primates.
36. Querec TD, Akondy RS, Lee EK et al.: Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).
37. Gaucher D, Therrien R, Kettaf N et al.: Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
38. Ghosh Z, Mallick B, Chakrabarti J: Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res. 37(4), 1035-1048 (2009).
39. Lu LF, Liston A: MicroRNA in the immune system, microRNA as an immune system. Immunology 127(3), 291-298 (2009).
40. Munger J, Bajad SU, Coller HA, Shenk T, Rabinowitz JD: Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog. 2(12), e132 (2006).
41. Munger J, Bennett BD, Parikh A et al.: Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26(10), 1179-1186 (2008).
42. Ringrose JH, Jeeninga RE, Berkhout B, Speijer D: Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J. Virol. 82(9), 4320-4330 (2008).
43. van 't Wout AB, Swain JV, Schindler M et al.: Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J. Virol. 79(15), 10053-10058 (2005).
44. Walters KA, Syder AJ, Lederer SL et al.: Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog. 5(1), e1000269 (2009).
45. Wikoff WR, Pendyala G, Siuzdak G, Fox HS: Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J. Clin. Invest. 118(7), 2661-2669 (2008).
46. Wikoff WR, Kalisak E, Trauger S, Manchester M, Siuzdak G: Response and recovery in the plasma metabolome tracks the acute LCMV-induced immune response. J. Proteome Res. 8(7), 3578-3587 (2009).
47. Peng X, Li Y, Walters KA et al.: Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 10, 373 (2009).